Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 4/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21262007 | 1.00 | HDAC1 (0.59) | HDAC1RETGPR119DRD4HTR1A | |
| SCHEMBL20468896 | 0.87 | HDAC1 (0.60) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL29600378 | 0.86 | HDAC1 (0.59) | HDAC1RETGPR119KCNK3KCNK9 | |
| SCHEMBL29356365 | 0.86 | HDAC1 (0.64) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL20354562 | 0.86 | HDAC1 (0.64) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL24428346 | 0.86 | HDAC1 (0.59) | HDAC1RETGPR119KCNK3KCNK9 | |
| SCHEMBL20456823 | 0.86 | HDAC1 (0.62) | HDAC1RETGPR119KCNK3KCNK9 | |
| SCHEMBL22909889 | 0.86 | HDAC1 (0.59) | HDAC1RETGPR119KCNK3KCNK9 | |
| SCHEMBL25310135 | 0.84 | GPR119 (0.59) | HDAC1RETGPR119KCNK3KCNK9 | |
| SCHEMBL25310645 | 0.84 | HDAC1 (0.57) | HDAC1RETGPR119KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139536-A1 | (4-PIPERAZIN-1YL)-4-ALKYL-PHTHALAZIN-1(2H)-ONE COMPOUNDS AS PARP7 INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| WO-2019153080-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-08-15 | — | — | WO | disclosed |
| EP-1359152-B1 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LAB (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | disclosed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1147112-B1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | HDAC1 281/4885RET 1770/4885GPR119 3895/4885 |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | HDAC1 199/4885RET 2243/4885GPR119 3611/4885 |
| US-20030225268-A1 | Diazabicyclic CNS active agents | GABRE, GRIN1, CNTN1 | HDAC1 957/4885RET 4112/4885GPR119 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.